Axsome Therapeutics (AXSM) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
12th Annual Cantor Fitzgerald Global Healthcare Conference summary
10 Sep, 2026Company overview and strategy
Focus on CNS disorders with three commercial products: AUVELITY, SYMBRAVO, and SUNOSI.
AUVELITY is approved for major depressive disorder and Alzheimer's disease agitation, with recent launch activities.
Deep pipeline includes NDA-stage AXS-12 for narcolepsy (PDUFA date May 1) and multiple phase III programs.
Recent expansion of commercial team and infrastructure, especially for AUVELITY.
Emphasis on execution in both commercial and pipeline development.
Pipeline and upcoming catalysts
ENGAGE phase III trial of solriamfetol (SUNOSI) in binge eating disorder with top-line results expected Q4.
Ongoing label expansion efforts for solriamfetol in MDD with EDS, shift work disorder, and ADHD.
AXS-05 SUMMIT phase III trial in smoking cessation recently initiated; enrollment underway.
AXS-14 (esreboxetine) in fibromyalgia and new programs AXS-17 (epilepsy) and AXS-20 (schizophrenia, Tourette) progressing.
AXS-20 acquired from Takeda, with phase III trial in schizophrenia planned and tech transfer ongoing.
AUVELITY commercial performance and market opportunity
Peak sales potential for AUVELITY in MDD and Alzheimer's agitation estimated at over $8 billion, based on low market share assumptions.
Sales force doubled from 300 to 600, with new LTC team for broader reach.
Exclusivity through Q1 2039 if pediatric indication is secured.
Early launch feedback highlights rapid reduction in agitation and favorable tolerability profile.
No black box warning for mortality risk in dementia, differentiating from competitors.
Latest events from Axsome Therapeutics
- AUVELITY momentum and an expanded pipeline underpin the next phase of growth.AXSM
UBS Global Biopharma Conference 2026 - AUVELITY momentum and a deep pipeline frame a $260M-revenue quarter.AXSM
3rd Annual Guggenheim Healthcare Innovation Conference - Revenue rose 52% as AUVELITY-led sales narrowed losses and pipeline milestones advanced.AXSM
Q3 2026 - Auvelity’s launch and pipeline expansion underpin an expected next phase of growth.AXSM
H.C. Wainwright 28th Annual Global Investment Conference - AUVELITY's growth accelerates in new indications, with strong pipeline and financial outlook.AXSM
Morgan Stanley 24th Annual Global Healthcare Conference - AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials.AXSM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue grew 46% to $218.4M, led by AUVELITY's Alzheimer's launch and pipeline progress.AXSM
Q2 2026 - Late-stage CNS pipeline targets high unmet needs with strong data and major commercial potential.AXSM
R&D Day 2025 - Symbravo gains FDA approval for acute migraine, offering rapid, sustained relief and broad market potential.AXSM
FDA Announcement